Identa Corp. (IDTA)
OTHER OTC:IDTA
Want to see IDTA full AI Analyst Report?
Top Page
Identa
(OTC:IDTA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.17
▼(-3.89% Downside)
Action:Reiterated
Date:04/07/26
The score is held back mainly by weakening financial quality (margin compression and sharply worse/volatile cash flow) and bearish technical trends (below key moving averages with negative MACD). The primary offset is a very low P/E valuation, which supports the score despite the operational and momentum risks.
Positive Factors
Improving Leverage
Lower leverage and rising equity reduce solvency risk and increase financial flexibility. Sustained below‑1.0 debt/equity gives capacity to withstand operating volatility, fund necessary investments, or absorb shocks over the next several months without immediate refinancing pressure.
Negative Factors
Cash Flow Volatility
A sharp collapse in operating and free cash flow in 2025, together with historical swings, signals unreliable cash conversion. Persistent volatility raises financing risk, constrains capital allocation, and makes the business more dependent on external funding or asset adjustments to cover operations in the near term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Leverage
Lower leverage and rising equity reduce solvency risk and increase financial flexibility. Sustained below‑1.0 debt/equity gives capacity to withstand operating volatility, fund necessary investments, or absorb shocks over the next several months without immediate refinancing pressure.
Read all positive factors
Identa (IDTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$714.18K
Dividend YieldN/A
Average Volume (3M)1.19K
Price to Earnings (P/E)5.9
Beta (1Y)-1.17
Revenue Growth40.37%
EPS Growth474.39%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,045,589
10 Day Avg. Volume1,429
30 Day Avg. Volume1,191
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.81
Price to Sales (P/S)0.53
P/FCF Ratio17.58
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda8.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Identa Business Overview & Revenue Model
Company Description
IDenta Corp. develops, manufactures, and supplies field detection and home diagnostics testing kits for narcotics and explosives, and forensic products in the homeland security and consumer markets worldwide. The company offers drug, explosives, a...
How the Company Makes Money
null...
Identa Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.34M | 1.46M | 1.05M | 1.34M | 1.39M |
| Gross Profit | 686.57K | 756.46K | 662.98K | 983.39K | 1.02M |
| EBITDA | 128.96K | 328.40K | 57.13K | 199.56K | 135.57K |
| Net Income | 99.04K | 258.34K | 14.64K | 162.71K | 69.18K |
Balance Sheet | |||||
| Total Assets | 1.92M | 1.66M | 1.53M | 1.56M | 1.23M |
| Cash, Cash Equivalents and Short-Term Investments | 379.42K | 735.95K | 264.29K | 368.90K | 347.15K |
| Total Debt | 645.20K | 640.23K | 785.37K | 820.28K | 511.63K |
| Total Liabilities | 1.04M | 921.01K | 1.01M | 1.10M | 799.32K |
| Stockholders Equity | 879.16K | 742.31K | 516.12K | 459.63K | 430.01K |
Cash Flow | |||||
| Free Cash Flow | 40.28K | 555.85K | -151.97K | 61.56K | -221.97K |
| Operating Cash Flow | 56.94K | 561.89K | -137.63K | 94.31K | -88.95K |
| Investing Cash Flow | -48.05K | -260.40K | -8.15K | -8.61K | -133.02K |
| Financing Cash Flow | -43.78K | -151.47K | -23.53K | -63.95K | 28.02K |
Identa Technical Analysis
Negative
0.18
Price Trends
0.19
Negative
0.21
Negative
0.22
Negative
Market Momentum
>-0.01
Negative
52.59
Neutral
136.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDTA, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.19, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.59 is Neutral, neither overbought nor oversold. The STOCH value of 136.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDTA.
Identa Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $714.18K | 5.90 | 4.97% | ― | 40.37% | 474.39% | |
45 Neutral | $6.77M | -0.47 | -174.16% | ― | 33.26% | 49.65% | |
44 Neutral | $7.05M | -1.06 | -537.60% | ― | ― | 98.32% | |
43 Neutral | $7.53M | -1.19 | -245.18% | ― | -35.75% | 47.29% | |
42 Neutral | $2.95M | -0.23 | -259.18% | ― | -44.78% | 92.56% |
* Healthcare Sector Average
IDTA
Identa
0.18
-0.38
-68.57%
BNBX
BNB Plus
0.38
-7.78
-95.32%
NDRA
ENDRA Life Sciences
5.35
2.24
72.03%
INBS
Intelligent Bio Solutions
2.63
-11.47
-81.35%
BIAF
bioAffinity Technologies, Inc.
1.62
-6.24
-79.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.